Eli Lilly has struck a deal to buy psychedelic drug developer AtaiBeckley for an initial $2.8 billion, weeks after the Trump ...

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker’s ...

Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.

CNBC's Angelica Peebles reports on the latest news on Eli Lilly. Got a confidential news tip? We want to hear from you. Sign ...

Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, forming an alliance focused on mapping ...

The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Eli Lilly is moving forward with its $6.5B Houston manufacturing site. New plans filed for the Generation Park project ...

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

However, Claude AI begs to differ from Trump. The AI agent recently sold its entire stake in Eli Lilly and Company (NYSE:LLY) ...

Eli Lilly has agreed to acquire psychedelic drugmaker AtaiBeckley for $6.75 per share in upfront cash, valuing the deal at ...